Resveratrol promotes lysosomal function via ER calcium-dependent TFEB activation to ameliorate lipid accumulation.
Level 5 - mechanism / opinion, no new human data
Bench laboratory mechanistic study without human subjects.
PubMed 33605996 · doi:10.1042/BCJ20200676
What was done
The authors investigated the molecular mechanism of resveratrol in reducing intracellular lipid accumulation using laboratory cellular assays. They assessed endoplasmic reticulum calcium signaling, protein phosphatase 2A (PP2A) activation, transcriptional factor EB (TFEB) dephosphorylation and nuclear translocation, downstream target gene expression for autophagic and lysosomal biogenesis, and the effect of genetic inhibition of TFEB on lipid clearance.
What was found
The abstract reports no numerical values, concentrations, or effect sizes. Resveratrol induced endoplasmic reticulum calcium signaling and activated PP2A, which bound to and dephosphorylated TFEB, promoting its nuclear translocation and the expression of autophagosome and lysosomal biogenesis genes. Genetic inhibition of TFEB significantly reduced resveratrol-mediated lipid clearance.
Why it matters
The study outlines an ER calcium–PP2A–TFEB signaling axis linking resveratrol to lysosomal and autophagic clearance of intracellular lipids, providing a molecular mechanism for its observed cellular effects.
Limits
This is purely an in vitro bench study without animal or human validation. The abstract reports no quantitative data, effect sizes, specific cell types, or tested drug concentrations. Findings in culture may not translate in vivo given resveratrol's known low oral bioavailability and rapid metabolism.
Cited by
- supports Resveratrol induces genes regulated by TFEB to enhance lysosomal system capacity.